Compare SKT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKT | IRON |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | 1993 | N/A |
| Metric | SKT | IRON |
|---|---|---|
| Price | $34.11 | $55.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $36.17 | ★ $110.08 |
| AVG Volume (30 Days) | ★ 1.2M | 674.2K |
| Earning Date | 02-24-2026 | 02-27-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $575,140,000.00 | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $35.99 | ★ N/A |
| Revenue Growth | ★ 10.01 | N/A |
| 52 Week Low | $28.69 | $30.82 |
| 52 Week High | $36.76 | $99.50 |
| Indicator | SKT | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 41.75 |
| Support Level | $33.25 | $70.60 |
| Resistance Level | $34.50 | $83.93 |
| Average True Range (ATR) | 0.75 | 4.09 |
| MACD | 0.16 | -0.51 |
| Stochastic Oscillator | 76.85 | 18.38 |
Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.